Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $67.70 USD
Change Today +5.99 / 9.71%
Volume 1.7M
As of 5:20 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

radius health inc (RDUS) Snapshot

Open
$64.48
Previous Close
$61.71
Day High
$69.16
Day Low
$63.03
52 Week High
06/30/15 - $69.16
52 Week Low
08/1/14 - $8.08
Market Cap
2.6B
Average Volume 10 Days
1.6M
EPS TTM
$-3.81
Shares Outstanding
37.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RADIUS HEALTH INC (RDUS)

Related News

No related news articles were found.

radius health inc (RDUS) Related Businessweek News

No Related Businessweek News Found

radius health inc (RDUS) Details

Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has completed Phase II clinical trial, which is used to increase bone mineral density. It is also developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase II proof of concept study for the treatment of vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer or other conditions. The company has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai Co. Ltd; and Lonza Group Ltd. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

25 Employees
Last Reported Date: 03/10/15
Founded in 2003

radius health inc (RDUS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $346.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $300.9K
Chief Medical Officer
Total Annual Compensation: $287.6K
Chief Development Officer
Total Annual Compensation: $321.3K
Compensation as of Fiscal Year 2014.

radius health inc (RDUS) Key Developments

Radius Announces Positive Top-Line Data From ACTIVExtend Trial Including Combined 25 Month Results

Radius Health, Inc. reported top line data from the first six months of ACTIVExtend and the 25 month combined data from ACTIVE and ACTIVExtend. Additionally, Radius is reporting new data from an exploratory analysis of major osteoporotic fractures in the ACTIVE trial. Radius previously reported positive results in December 2014 for the Phase 3 ACTIVE Trial – meeting the primary endpoint of new vertebral fracture reduction (-86%, p < 0.0001) and secondary endpoints of non-vertebral fracture reduction (-43%, p = 0.0489) and BMD increases at Spine (18M, 9.20% p < 0.0001), Femoral Neck (18M 2.90% p < 0.0001) and Total Hip (18M 3.44% p < 0.0001). ACTIVExtend results show that the group previously treated with abaloparatide had no new vertebral fractures during the first six months on alendronate. From the start of the ACTIVE study, this group showed an 87% reduction in new vertebral fractures (p < 0.0001), 52% reduction in non-vertebral fractures (p = 0.0168), 48% reduction in clinical fractures (p = 0.0139), and a 58% reduction in major osteoporotic fractures (p = 0.0122) over the 25-month period. A recent exploratory analysis of the ACTIVE trial showed that, for major osteoporotic fractures, there was a 67% reduction in major osteoporotic fractures (p = 0.0014) for the abaloparatide treatment group versus placebo, and a 53% reduction in major osteoporotic fractures (p = 0.0437) for the abaloparatide treatment group as compared to teriparatide. Over the 25-month period, patients in the abaloparatide-alendronate treatment group on average achieved a 12.8% increase in BMD at the lumbar spine, a 5.5% increase in BMD at total hip, and a 4.5% increase in BMD at the femoral neck. In this treatment group, 20.4% of patients achieved a 6% increase or greater in BMD at all three sites (i.e., lumbar spine, total hip, and femoral neck).

Radius Health, Inc. - Special Call

To discuss on positive top-line data from ACTIVExtend trial including combined 25 month results

Radius Health, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 02:00 PM

Radius Health, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Robert E. Ward, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDUS:US $67.70 USD +5.99

RDUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
West Pharmaceutical Services Inc $58.08 USD +0.19
View Industry Companies
 

Industry Analysis

RDUS

Industry Average

Valuation RDUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RADIUS HEALTH INC, please visit www.radiuspharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.